Bioymifi suppresses Burkitt's lymphoma cell line proliferation via cell cycle arrest and apoptosis


Creative Commons License

TERZİ H., Inanir M.

TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, cilt.21, sa.9, ss.1837-1843, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 9
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4314/tjpr.v21i9.4
  • Dergi Adı: TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.1837-1843
  • Anahtar Kelimeler: Apoptosis, Bioymifi, Cell cycle, Death receptor, DNA damage, TUMOR-CELL, PHASE-II, DEATH, CARBOPLATIN, MAPATUMUMAB, PACLITAXEL, ANTIBODY, CANCER, TRIAL, TRAIL
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Purpose: To find a new treatment alternative for Burkitt's lymphoma, one of the B cell-derived nonHodgkin's lymphomas that has an extremely aggressive growth profile with a high mortality rate. Methods: Bioymifi (death receptor agonist) was administered at various doses to Human Burkitt's Lymphoma Raji cell lines, and cell proliferation was evaluated using XTT analysis. Apoptosis induction and cell cycle analysis were assessed using flow cytometry. Results: Bioymifi exhibited good cytotoxicity in Raji cell lines with IC50 value of 29.5 mu M. Furthermore, results of apoptosis induction and cell cycle analysis indicated that Bioymifi had potent anti-proliferative activity through sub-S cell cycle arrest and stimulation of apoptosis (p < 0.05). Conclusion: Bioymifi has anticancer potentials against Human Burkitt's Lymphoma Raji cell lines. Further pharmacological studies will be required to establish the mechanism of action.